Intracellular disposition of fludarabine triphosphate in human natural killer cells
- PMID: 18781301
- PMCID: PMC2648818
- DOI: 10.1007/s00280-008-0829-0
Intracellular disposition of fludarabine triphosphate in human natural killer cells
Abstract
Purpose: Fludarabine is a key component of several reduced-intensity conditioning regimens for hematopoietic cell transplantation (HCT). Shortly after reduced-intensity conditioning, the percent of donor natural killer (NK) cells has been associated with progression-free survival. Insufficient suppression of the recipient's NK cells by fludarabine may lead to lower donor chimerism; however, the effect of fludarabine upon NK cells is poorly understood. Thus, in purified human NK cells we evaluated the uptake and activation of fludarabine to its active metabolite, fludarabine triphosphate (F-ara-ATP), and assessed the degree of interindividual variability in F-ara-ATP accumulation.
Methods: Intracellular F-ara-ATP was measured in purified NK cells isolated from healthy volunteers (n = 6) after ex vivo exposure to fludarabine. Gene expression levels of the relevant transporters and enzymes involved in fludarabine uptake and activation were also measured in these cells.
Results: F-ara-ATP accumulation (mean +/- SD) was 6.00 +/- 3.67 pmol/1 x 10(6) cells/4 h, comparable to average levels previously observed in CD4(+) and CD8(+) T-lymphocytes. We observed considerable variability in F-ara-ATP accumulation and mRNA expression of transporters and enzymes relevant to F-ara-ATP accumulation in NK cells from different healthy volunteers.
Conclusions: Human NK cells have the ability to form F-ara-ATP intracellularly and large interindividual variability was observed in healthy volunteers. Further studies are needed to evaluate whether F-ara-ATP accumulation in NK cells are associated with apoptosis and clinical outcomes.
Figures
References
-
- Deeg HJ, Maris MB, Scott BL, Warren EH. Optimization of allogeneic transplant conditioning: not the time for dogma. Leukemia. 2006;20:1701–5. - PubMed
-
- Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756–63. - PubMed
-
- Champlin R, Khouri I, Anderlini P, De Lima M, Hosing C, McMannis J, Molldrem J, Ueno N, Giralt S. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Biology and current indications. Oncology (Williston Park) 2003;17:94–100. discussion 103-7. - PubMed
-
- Storb R. Mixed allogeneic chimerism and graft-versus-leukemia effects in acute myeloid leukemia. Leukemia. 2002;16:753–4. - PubMed
-
- Baron F, Storb RG, Sandmaier B, Gisburne S, Shin S, Stroup P, Baker J, Maris M, Maloney D, Heimfeld S, Grumet FC, Chauncey T, Blume K, Little MT. Assessing Donor Chimerism Level Among CD3 T, CD4 T, CD8 T AND NK Cells Predicts Subsequent Graft Rejection, GVHD and Relapse After Allogeneic HCT with Nonmyeloablative Conditioning; ASBMT Tandem BMT Meetings; 2005; T.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials